

Susan C Modesitt

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8377941/publications.pdf>

Version: 2024-02-01

49
papers

1,099
citations

471509

17
h-index

434195

31
g-index

49
all docs

49
docs citations

49
times ranked

1862
citing authors

#	ARTICLE	IF	CITATIONS
1	Beneficial effects of exercise on chemotherapy-induced peripheral neuropathy and sleep disturbance: A review of literature and proposed mechanisms. <i>Gynecologic Oncology Reports</i> , 2022, 39, 100927.	0.6	11
2	Effect of risk-reducing salpingo-oophorectomy on sex steroid hormone serum levels among postmenopausal women: an NRG Oncology/Gynecologic Oncology Group study. <i>American Journal of Obstetrics and Gynecology</i> , 2022, , .	1.3	1
3	Perioperative Impact of Widespread Implementation of an Enhanced Recovery Protocol on Short-term Outcomes in Cancer Patients. <i>Journal of Gastrointestinal Surgery</i> , 2021, 25, 1316-1318.	1.7	0
4	“Moving Away From Cancer” Prospective Exercise Trial for Female Rural Cancer Survivors: How Can We Step It Up?. <i>JCO Oncology Practice</i> , 2021, 17, e16-e25.	2.9	2
5	Characteristics of Immune Memory and Effector Activity to Cancer-Expressed MHC Class I Phosphopeptides Differ in Healthy Donors and Ovarian Cancer Patients. <i>Cancer Immunology Research</i> , 2021, 9, 1327-1341.	3.4	4
6	Patient-reported outcome changes at the end of life in recurrent platinum-resistant ovarian cancer: An NRG oncology/GOG study. <i>Gynecologic Oncology</i> , 2021, 163, 392-397.	1.4	0
7	Phase II study of atezolizumab in combination with bevacizumab in patients with advanced cervical cancer. , 2020, 8, e001126.		54
8	Neoadjuvant chemotherapy with paclitaxel/carboplatin/bevacizumab in advanced vulvar cancer: Time to rethink standard of care?. <i>Gynecologic Oncology Reports</i> , 2020, 34, 100631.	0.6	5
9	Mechanisms to increase cascade testing in hereditary breast and ovarian cancer: Impact of introducing standardized communication aids into genetic counseling. <i>Journal of Obstetrics and Gynaecology Research</i> , 2020, 46, 1835-1841.	1.3	10
10	Adjuvant treatment improves overall survival in women with high-intermediate risk early-stage endometrial cancer with lymphovascular space invasion. <i>International Journal of Gynecological Cancer</i> , 2020, 30, 1738-1747.	2.5	8
11	Optimal age for genetic cancer predisposition testing in hereditary SMARCA4 Ovarian Cancer Families: How young is too young?. <i>Gynecologic Oncology Reports</i> , 2020, 32, 100569.	0.6	5
12	Evaluation of breast screening strategies in a high risk breast and ovarian cancer clinic. <i>Gynecologic Oncology Reports</i> , 2020, 33, 100587.	0.6	0
13	Adjuvant therapy for early stage, endometrial cancer with lymphovascular space invasion: Is there a role for chemotherapy?. <i>Gynecologic Oncology</i> , 2020, 156, 568-574.	1.4	15
14	Safety lead-in of the MEK inhibitor trametinib in combination with GSK2141795, an AKT inhibitor, in patients with recurrent endometrial cancer: An NRG Oncology/GOG study. <i>Gynecologic Oncology</i> , 2019, 155, 420-428.	1.4	28
15	Phase II Trial of Chemopreventive Effects of Levonorgestrel on Ovarian and Fallopian Tube Epithelium in Women at High Risk for Ovarian Cancer: An NRG Oncology Group/GOG Study. <i>Cancer Prevention Research</i> , 2019, 12, 401-412.	1.5	5
16	Genetic counseling referral for ovarian cancer patients: a call to action. <i>Familial Cancer</i> , 2019, 18, 303-309.	1.9	7
17	Cases and evidence for panel testing in cancer genetics: Is site-specific testing dead?. <i>Journal of Genetic Counseling</i> , 2019, 28, 700-707.	1.6	5
18	Evaluation of screening and risk-reducing surgery for women followed in a high-risk breast/ovarian cancer clinic: it is all about the tubes in BRCA mutation carriers. <i>Gynecologic Oncology Reports</i> , 2019, 28, 18-22.	0.6	7

#	ARTICLE	IF	CITATIONS
19	Enhanced recovery program for minimally invasive and vaginal urogynecologic surgery. <i>International Urogynecology Journal</i> , 2019, 30, 313-321.	1.4	33
20	Missing information in statewide and national cancer databases: Correlation with health risk factors, geographic disparities, and outcomes. <i>Gynecologic Oncology</i> , 2019, 152, 119-126.	1.4	5
21	When to Worry about Cancer: Concurrent Carcinoma and Recurrence in Borderline Ovarian Tumors. <i>Southern Medical Journal</i> , 2019, 112, 634-638.	0.7	2
22	Hereditary Cancers in Gynecology. <i>Obstetrics and Gynecology Clinics of North America</i> , 2018, 45, 155-173.	1.9	4
23	Quality of life, symptoms and care needs in patients with persistent or recurrent platinum-resistant ovarian cancer: An NRG Oncology/Gynecologic Oncology Group study. <i>Gynecologic Oncology</i> , 2018, 150, 119-126.	1.4	15
24	Endometrial cancer in an increasingly obese population: Exploring alternative options when surgery may not cut it. <i>Gynecologic Oncology Reports</i> , 2018, 25, 30-34.	0.6	11
25	Clinicopathologic characterization of breast carcinomas in patients with non-BRCA germline mutations: results from a single institution's high-risk population. <i>Human Pathology</i> , 2018, 82, 20-31.	2.0	5
26	Intussusception as a rare cause of bowel obstruction in a woman with recurrent ovarian cancer. <i>Gynecologic Oncology Reports</i> , 2018, 26, 4-6.	0.6	1
27	Analysis of the circular RNA transcriptome in endometrial cancer. <i>Oncotarget</i> , 2018, 9, 5786-5796.	1.8	58
28	Current and future role of genetic screening in gynecologic malignancies. <i>American Journal of Obstetrics and Gynecology</i> , 2017, 217, 512-521.	1.3	34
29	Transcriptome landscape of long intergenic non-coding RNAs in endometrial cancer. <i>Gynecologic Oncology</i> , 2017, 147, 654-662.	1.4	55
30	The impact of physician burnout on clinical and academic productivity of gynecologic oncologists: A decision analysis. <i>Gynecologic Oncology</i> , 2017, 146, 642-646.	1.4	31
31	Rectosigmoid Perforation and Sepsis from Endometriosis in Early Pregnancy. <i>Surgical Infections Case Reports</i> , 2016, 1, 32-34.	0.1	0
32	Enhanced Recovery Implementation in Major Gynecologic Surgeries. <i>Obstetrics and Gynecology</i> , 2016, 128, 457-466.	2.4	154
33	The emerging role of long non-coding RNAs in endometrial cancer. <i>Cancer Genetics</i> , 2016, 209, 445-455.	0.4	39
34	Body mass index and mortality in endometrial cancer: A systematic review and meta-analysis. <i>Gynecologic Oncology</i> , 2016, 140, 184-190.	1.4	120
35	Hormonal Contraceptives for Endometrial Cancer Prevention in Obese and High-Risk Women in Virginia. <i>Southern Medical Journal</i> , 2016, 109, 621-627.	0.7	2
36	Serous Tubal Intraepithelial Carcinoma: An Incidental Finding at the Time of Prophylactic Bilateral Salpingo-Oophorectomy. <i>Case Reports in Obstetrics and Gynecology</i> , 2015, 2015, 1-4.	0.3	6

#	ARTICLE	IF	CITATIONS
37	Protecting the Next Generation. <i>Social Marketing Quarterly</i> , 2015, 21, 173-188.	1.7	20
38	Women at extreme risk for obesity-related carcinogenesis: Baseline endometrial pathology and impact of bariatric surgery on weight, metabolic profiles and quality of life. <i>Gynecologic Oncology</i> , 2015, 138, 238-245.	1.4	57
39	Perceptions of obesity and cancer risk in female bariatric surgery candidates: Highlighting the need for physician action for unsuspectingly obese and high risk patients. <i>Gynecologic Oncology</i> , 2014, 133, 73-77.	1.4	12
40	Metabolic Vulnerabilities in Endometrial Cancer. <i>Cancer Research</i> , 2014, 74, 5832-5845.	0.9	88
41	Vulvar necrotizing soft tissue infection: A review of a multi-disciplinary surgical emergency and management in the modern era. <i>Gynecologic Oncology Case Reports</i> , 2013, 5, 6-9.	0.9	7
42	What is New in Gynecologic Oncology?. <i>Obstetrics and Gynecology</i> , 2013, 121, 872-873.	2.4	3
43	Post Approval Human Papillomavirus Vaccine Uptake Is Higher in Minorities Compared to Whites in Girls Presenting for Well-Child Care. <i>Vaccines</i> , 2013, 1, 250-261.	4.4	6
44	Not All Fat Is Equal. <i>International Journal of Gynecological Cancer</i> , 2012, 22, 732-741.	2.5	30
45	Coexisting atypical polypoid adenomyoma and endometrioid endometrial carcinoma in a young woman with Cowden Syndrome: Case report and implications for screening and prevention. <i>Gynecologic Oncology Case Reports</i> , 2012, 2, 29-31.	0.9	9
46	Morbidly obese women with and without endometrial cancer: Are there differences in measured physical fitness, body composition, or hormones?. <i>Gynecologic Oncology</i> , 2012, 124, 431-436.	1.4	26
47	In vitro and in vivo histone deacetylase inhibitor therapy with vorinostat and paclitaxel in ovarian cancer models: Does timing matter?. <i>Gynecologic Oncology</i> , 2010, 119, 351-357.	1.4	25
48	Recurrent epithelial ovarian cancer: pharmacotherapy and novel therapeutics. <i>Expert Opinion on Pharmacotherapy</i> , 2007, 8, 2293-2305.	1.8	22
49	Impact of body mass index on treatment outcomes in endometrial cancer patients receiving doxorubicin and cisplatin: A Gynecologic Oncology Group study. <i>Gynecologic Oncology</i> , 2007, 105, 59-65.	1.4	52